Evidence map›Paper›PMID 39576637›Full record

Trial reportJAMA network open2024

Nurse Care Management of Opioid Use Disorder Treatment After 3 Years: A Secondary Analysis of the PROUD Cluster Randomized Clinical Trial.

Gwen T Lapham, Noorie Hyun, Jennifer F Bobb, Paige D Wartko, Abigail G Matthews, Onchee Yu, Jennifer McCormack, Amy K Lee, David S Liu, Jeffrey H Samet and 8 more

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in JAMA network open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03407638 (PRimary Care Opioid Use Disorders Treatment), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03407638 nacompletednot on this map

PRimary Care Opioid Use Disorders Treatment (PROUD) Trial

TypeinterventionalSponsorKaiser PermanenteRan2018 to 2020Enrolled377,373ConditionsOpioid-use DisorderArmsPROUD Intervention
3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Gwen T LaphamKaiser Permanente Washington Health Research Institute, Seattle, Washington.
Noorie HyunKaiser Permanente Washington Health Research Institute, Seattle, Washington.
Jennifer F BobbKaiser Permanente Washington Health Research Institute, Seattle, Washington.
Paige D WartkoKaiser Permanente Washington Health Research Institute, Seattle, Washington.
Abigail G MatthewsThe Emmes Company, Rockville, Maryland.
Onchee YuKaiser Permanente Washington Health Research Institute, Seattle, Washington.
Jennifer McCormackThe Emmes Company, Rockville, Maryland.
Amy K LeeKaiser Permanente Washington Health Research Institute, Seattle, Washington.
David S LiuNational Institute on Drug Abuse Center for Clinical Trials Network, North Bethesda, Maryland.
Jeffrey H SametBoston University Chobanian and Avedisian School of Medicine and the School of Public Health, Boston Medical Center, Boston, Massachusetts.
Mohammad Zare-MehrjerdiDepartment of Family and Community Medicine, UTHealth Houston McGovern Medical School, Houston, Texas.
Jordan M BraciszewskiCenter for Health Policy and Health Services Research, Henry Ford Health, Detroit, Michigan.
Mark T MurphyMultiCare Health System, Tacoma, Washington.
Julia H ArnstenMontefiore Medical Center, Bronx, New York.
Viviana HorigianDepartment of Public Health Sciences, University of Miami Miller School of Medicine, Miami, Florida.
Ryan M CaldeiroMental Health and Wellness Department, Kaiser Permanente Washington.
Megan AddisKaiser Permanente Washington Health Research Institute, Seattle, Washington.
Katharine A BradleyKaiser Permanente Washington Health Research Institute, Seattle, Washington.

Funding

Project-003UG1DA013035 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Aimee N Campbell, Jennifer McNeely · 2015 to 2026
$130.3M
The National Drug Abuse Treatment Clinical Trials NetworkUG1DA015831 · NIDA · YALE UNIVERSITY · PI Gail D'Onofrio, Roger D. Weiss · 2015 to 2026
$110.8M
Project-004UG1DA020024 · NIDA · UT SOUTHWESTERN MEDICAL CENTER · PI Steven J Shoptaw, MADHUKAR H. TRIVEDI · 2015 to 2026
$71.6M
The Florida Node Alliance of the National Drug Abuse Treatment Clinical Trials NetworkUG1DA013720 · NIDA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Daniel J Feaster, Viviana Elizabeth Horigian · 2015 to 2026
$50.6M
Project-002UG1DA040314 · NIDA · KAISER FOUNDATION RESEARCH INSTITUTE · PI Ingrid A Binswanger, CYNTHIA I CAMPBELL · 2015 to 2026
$34.9M
Clinical Trials Network: Pacific Northwest Node (CTN-0082, -0131, -0139 and dissemination library)UG1DA013714 · NIDA · UNIVERSITY OF WASHINGTON · PI Mary Akiko Hatch, John M. Roll · 2015 to 2026
$19.8M
Training Program on HIV and Substance Use in the Criminal Justice SystemT32DA037801 · NIDA · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Nabila El-Bassel, Lisa R Metsch · 2014 to 2026
$5.7M
NIDA NIH HHS T32 DA037801NIDA NIH HHS UG1 DA013035NIDA NIH HHS UG1 DA013714NIDA NIH HHS UG1 DA013720NIDA NIH HHS UG1 DA015831NIDA NIH HHS UG1 DA020024NIDA NIH HHS UG1 DA040314
6 · The paper itself

Abstract

Importance: The Primary Care Opioid Use Disorders (PROUD) treatment trial was a 2-year implementation trial that demonstrated the Massachusetts office-based addiction treatment (OBAT) model of nurse care management for opioid use disorder (OUD) increased OUD treatment in the 2 years after implementation began (8.2 more patient-years of OUD treatment per 10 000 primary care patients). The intervention was continued for a third year, permitting evaluation of 3-year outcomes. Objective: To compare OUD medication treatment in intervention and usual care clinics over 3 years of implementation. Design, Setting, and Participants: This is a preplanned secondary analysis of a cluster randomized implementation trial, conducted in 6 health systems in 5 states (2 primary care clinics per health system) with clinic randomization stratified by system (assignment notification February 28, 2018 [August 31, 2018, in 1 system]). Data were obtained from electronic health records and insurance claims. Eligible patients were those aged 16 to 90 years visiting intervention or usual care clinics from 3 years before to 2 years after randomization. Patients new to clinics during the third year after randomization could not be included because COVID-19-era transitions to virtual care precluded assignment of patients to clinics. Data analysis occurred from November 2023 to September 2024. Intervention: Clinics were randomized to intervention or care as usual. Intervention included 3 implementation components: salary for 1 full-time OBAT nurse per intervention clinic; training and ongoing technical assistance for nurses; and 3 or more primary care buprenorphine prescribers. Main Outcome and Measures: Patient-years of OUD treatment (buprenorphine or extended-release naltrexone) per 10 000 primary care patients in the 3 years postrandomization. Mixed-effect models adjusted for baseline values of the outcome and included a health system-specific random intercept to account for correlation of clinic pairs within a system. Results: Prerandomization, a total of 290 071 primary care patients were seen, including 130 618 in intervention clinics (mean [SD] age, 48.6 [17.7] years; mean [SD] female, 59.3% [4.0%]) and 159 453 in usual care clinics (mean [SD] age, 47.2 [17.5] years; mean [SD] female, 64.0% [5.3%]). Over 3 years postrandomization, intervention clinics provided 19.7 (95% CI, 11.1-28.4) more patient-years of OUD treatment per 10 000 primary care patients compared with usual care clinics. Conclusions: In this secondary analysis of the PROUD cluster randomized trial, after an added year of the intervention, OUD treatment continued to increase in intervention clinics compared with usual care. The treatment increase over 3 years exceeded that of the first 2 years, suggesting that implementation of the Massachusetts OBAT model leads to ongoing increases in OUD treatment among primary care patients in the third year of implementation. Trial Registration: ClinicalTrials.gov Identifier: NCT03407638.

Indexed as

Opioid-Related DisordersPrimary Health CareAdolescentAdultAgedAged, 80 and overBuprenorphineCOVID-19FemaleHumansMaleMassachusettsMiddle AgedNursing CareOpiate Substitution TreatmentYoung AdultBuprenorphine

Identifiers

PMID39576637
PMCPMC11584924

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.